Compare DTI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | ACHV |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 172.0M |
| IPO Year | 2021 | 2018 |
| Metric | DTI | ACHV |
|---|---|---|
| Price | $2.73 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 272.1K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,446,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.65 | $2.00 |
| 52 Week High | $4.69 | $6.15 |
| Indicator | DTI | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 53.31 |
| Support Level | $2.45 | $4.04 |
| Resistance Level | $2.72 | $5.30 |
| Average True Range (ATR) | 0.10 | 0.38 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 11.25 | 56.82 |
Drilling Tools International Corp is an oilfield services company that designs, engineers, and manufactures rental-focused tools used in onshore and offshore horizontal and directional drilling operations, as well as solutions across the well life cycle. It operates through two geographic segments: Western Hemisphere and Eastern Hemisphere. The Western Hemisphere, which generates the majority of revenue, provides downhole drilling tools and rental services for onshore and offshore operations across North America and Latin America, supported by service centers in the U.S. and Canada. The Eastern Hemisphere covers Europe, the Middle East, and Asia-Pacific, where the company offers drilling and well lifecycle solutions through international service centers across the EMEA and APAC regions.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.